卡博替尼的临床研究进展
The Clinical Research Progress of Cabozantinib
DOI: 10.12677/HJMCe.2018.63009, PDF,    科研立项经费支持
作者: 陆兆辉, 周海嫔*：滁州学院，材料与化学工程学院，安徽 滁州
关键词: 多靶点抗癌药物；卡博替尼；临床应用；应用前景；Multitargeted Anti-Tumor Drugs； Cabozantinib； Clinical Application； Application Prospect
摘要: 卡博替尼是新型多靶点抗癌药物，现用于转移性甲状腺髓样癌和晚期肾癌的治疗，并对其他的肿瘤具有一定的临床疗效。结合国内外研究进展，本文综述卡博替尼的临床应用现状及应用前景，希望能对卡博替尼的研究及应用提供参考。
Abstract: Cabozantinib is a novel multitargeted anti-tumor drug, which has been approved by FDA for the treatment of both progressive metastatic medullary thyroid cancer and advanced renal cell carci-noma, and is being investigated for various other malignancies. In this paper, we reviewed the clinical application and clinical research frontier of cabozantinib according to the recent study, wishing to provide the reference to the future research and application of cabozantinib.
文章引用：陆兆辉, 周海嫔. 卡博替尼的临床研究进展[J]. 药物化学, 2018, 6(3): 62-66. https://doi.org/10.12677/HJMCe.2018.63009

参考文献

[1] Tridente, G. (2017) Adverse Events and Oncotargeted Kinase Inhibitors. Academic Press, Cambridge, 457-480. [Google Scholar] [CrossRef] 
[2] 张秀颖, 刘尧, 白秋江, 等. 新型分子靶向抗癌药物卡博替尼[J]. 医药导报, 2013, 32(11): 1468-1470.
[3] Traynor, K. (2013) Cabozantinib Approved for Advanced Medullarythyroid Cancer. Amer-ican Journal of Health-System Pharmacy, 70, 88.
[4] 杨影, 方艳秋, 谭岩. 卡博替尼治疗晚期甲状腺髓样癌的研究进展[J]. 中国社区医师, 2014, 30(24): 10.
[5] 郑希元, 姜汉杰, 蒲小平. 抗甲状腺髓样癌新药卡博替尼[J]. 中国新药杂志, 2013, 22(17): 1990-1993.
[6] Procopio, G. and Prisciandaro, M. (2018) Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data from an Italian Managed Access Program. Clinical Genitourinary Cancer, 4, in Press. [Google Scholar] [CrossRef] [PubMed]
[7] 郭放, 郑振东, 谢晓冬. 晚期肾癌分子靶向治疗新进展[J]. 中国肿瘤临床, 2016, 43(22): 977-980.
[8] 朱国栋. Clin Cancer Res: 卡博替尼获美国食品及药品管理局批准用于晚期肾癌患者治疗[J]. 现代泌尿外科杂志, 2017, 22(4): 306-307.
[9] Choueiri, T.K., Hessel, C., Halabi, S., et al. (2018) Cabozantinib versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Pro-gression-Free Survival by Independent Review and Overall Survival Update. European Journal of Cancer, 94, 115-125. [Google Scholar] [CrossRef] [PubMed]
[10] Viteri S, Rosell R, et al. (2017) Ceritinib and Cabozantinib: New Tyrosine Kinase Inhibitors Improve Treatment Options for Non-Small Cell Lung Cancer Patients. Translational Cancer Research, 6, 643-646. [Google Scholar] [CrossRef] 
[11] Peters, M., Linton, B., Miksad, R.A., et al. (2017) Cabozantinib in the Treatment of Hepatocellular Carcinoma. Future Oncology, 13, 1915-1929. [Google Scholar] [CrossRef] [PubMed]
[12] Patnaik, A.S., et al. (2017) Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. Cancer Discovery, 7, 750-765. [Google Scholar] [CrossRef] 
[13] Smith, M.R., Sweeney, C.J., Corn, P.G., et al. (2014) Cabozantinib in Chemo-therapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study. Journal of Clinical Oncology, 32, 30. [Google Scholar] [CrossRef] 
[14] Ducasse, M., Brown, M.A., et al. (2006) Epigenetic Aberrations and Cancer. Molecular Cancer, 5, 60-75. [Google Scholar] [CrossRef] [PubMed]
[15] Vergote, I.B., Smith, D.C., Berger, R., et al. (2017) A Phase 2 Randomised Discon-tinuation Trial of Cabozantinib in Patients with Ovarian Carcinoma. European Journal of Cancer, 83, 229-236. [Google Scholar] [CrossRef] [PubMed]
[16] Lu, J.-W., Wang, A.-N., Liao, H.-A., et al. (2016) Cabozantinib Is Selectively Cy-totoxic in Acute Myeloid Leukemia Cells with FLT3-Internal Tandem Duplication (FLT3-ITD). Cancer Letters, 376, 218-225. [Google Scholar] [CrossRef] [PubMed]
[17] Shintani, T., Kusuhara, Y., Daizumoto, K., et al. (2017) The Involvement of He-patocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells. Urology, 101, 169.e7-169.e13. [Google Scholar] [CrossRef] [PubMed]
[18] 肖晴, 龙敏, 刘一帆. 卡博替尼抵抗产单核细胞李斯特菌感染的体内实验研究[J]. 山西医科大学学报, 2017, 48(12): 1255-1259.
[19] 杜蕾. c-Met阻断剂抑制产单核细胞李斯特菌胞内感染机制的研究[D]: [硕士学位论文]. 广州: 南方医科大学, 2016.
[20] 杜蕾, 曾庆, 何肖龙, 等. 卡博替尼抑制产单核细胞李斯特菌侵袭Caco-2细胞的机制[J]. 南方医科大学学报, 2016, 36(2): 226-231.
[21] Markowitz, J.N. and Fancher, K.M. (2017) Cabozantinib: A Multi-Targeted Oral Tyrosine Kinase Inhibitor. Pharmacotherapy, 38, 357-369. [Google Scholar] [CrossRef] [PubMed]